Reconfiguring photonic metamaterials

Dynamic control over metamaterial optical properties is key for the use of metamaterials as active elements ranging from modulators and switches to tunable filters and programmable transformation optics devices. Here we exploit that the properties of virtually any metamaterial structure strongly depend on the spatial arrangement of its components. By manufacturing plasmonic metamaterials on a grid of elastic dielectric bridges of nanoscale thickness, we are able to dynamically rearrange sub-micron sized plasmonic building blocks across the entire metamaterial array (see figure). We demonstrate that this approach provides a flexible platform for continuous tuning, fast modulation and high-contrast switching of photonic metamaterials via external stimuli such as electric voltages, optical excitation and magnetic fields

Optical magnetic response in all-dielectric metamaterial

We experimentally demonstrate a new mechanism to achieve magnetic resonances at visible and near-infrared frequencies in purely dielectric metamaterials, realized through a coupling between pairs of closely spaced, dissimilar dielectric rods

Next generation perfusion process development for production of biologics

Please click Additional Files below to see the full abstract

Upstream control strategy development for afucosylated species in mAb biomanufacturing

Please click Additional Files below to see the full abstract

Bioreactor Suspension Culture: Differentiation and Production of Cardiomyocyte Spheroids From Human Induced Pluripotent Stem Cells

Human induced-pluripotent stem cells (hiPSCs) can be efficiently differentiated into cardiomyocytes (hiPSC-CMs) via the GiWi method, which uses small-molecule inhibitors of glycogen synthase kinase (GSK) and tankyrase to first activate and then suppress Wnt signaling. However, this method is typically conducted in 6-well culture plates with two-dimensional (2D) cell sheets, and consequently, cannot be easily scaled to produce the large numbers of hiPSC-CMs needed for clinical applications. Cell suspensions are more suitable than 2D systems for commercial biomanufacturing, and suspended hiPSCs form free-floating aggregates (i.e., spheroids) that can also be differentiated into hiPSC-CMs. Here, we introduce a protocol for differentiating suspensions of hiPSC spheroids into cardiomyocytes that is based on the GiWi method. After optimization based on cardiac troponin T staining, the purity of hiPSC-CMs differentiated via our novel protocol exceeded 98% with yields of about 1.5 million hiPSC-CMs/mL and less between-batch purity variability than hiPSC-CMs produced in 2D cultures; furthermore, the culture volume could be increased ∼10-fold to 30 mL with no need for re-optimization, which suggests that this method can serve as a framework for large-scale hiPSC-CM production

Giant nonlinearity of an optically reconfigurable plasmonic metamaterial

Dataset for J. Y. Ou, E. Plum, J. Zhang, and N. I. Zheludev (2016), Giant nonlinearity of an optically reconfigurable plasmonic metamaterial. Advanced Materials, 28, 729-733. doi: 10.1002/adma.201504467 </span

Rebalancing Redox to Improve Biobutanol Production by Clostridium tyrobutyricum

Biobutanol is a sustainable green biofuel that can substitute for gasoline. Carbon flux has been redistributed in Clostridium tyrobutyricum via metabolic cell engineering to produce biobutanol. However, the lack of reducing power hampered the further improvement of butanol production. The objective of this study was to improve butanol production by rebalancing redox. Firstly, a metabolically-engineered mutant CTC-fdh-adhE2 was constructed by introducing heterologous formate dehydrogenase (fdh) and bifunctional aldehyde/alcohol dehydrogenase (adhE2) simultaneously into wild-type C. tyrobutyricum. The mutant evaluation indicated that the fdh-catalyzed NADH-producing pathway improved butanol titer by 2.15-fold in the serum bottle and 2.72-fold in the bioreactor. Secondly, the medium supplements that could shift metabolic flux to improve the production of butyrate or butanol were identified, including vanadate, acetamide, sodium formate, vitamin B12 and methyl viologen hydrate. Finally, the free-cell fermentation produced 12.34 g/L of butanol from glucose using the mutant CTC-fdh-adhE2, which was 3.88-fold higher than that produced by the control mutant CTC-adhE2. This study demonstrated that the redox engineering in C. tyrobutyricum could greatly increase butanol production

Control of metal color using surface relief metamaterial nanostructuring

Continuously metallic metamaterials can be frequency-selective, providing a means to engineer the color of uncoated metal surfaces

Novel biomanufacturing platform for large-scale and high-quality human T cells production

Abstract The adoptive transfer of human T cells or genetically-engineered T cells with cancer-targeting receptors has shown tremendous promise for eradicating tumors in clinical trials. The objective of this study was to develop a novel T cell biomanufacturing platform using stirred-tank bioreactor for large-scale and high-quality cellular production. First, various factors, such as bioreactor parameters, media, supplements, stimulation, seed age, and donors, were investigated. A serum-free fed-batch bioproduction process was developed to achieve 1000-fold expansion within 8 days after first stimulation and another 500-fold expansion with second stimulation. Second, this biomanufacturing process was successfully scaled up in bioreactor with dilution factor of 10, and the robustness and reproducibility of the process was confirmed by the inclusion of different donors’ T cells of various qualities. Finally, T cell quality was monitored using 12 surface markers and 3 intracellular cytokines as the critical quality assessment criteria in early, middle and late stages of cell production. In this study, a new biomanufacturing platform was created to produce reliable, reproducible, high-quality, and large-quantity (i.e. > 5 billion) human T cells in stirred-tank bioreactor. This platform is compatible with the production systems of monoclonal antibodies, vaccines, and other therapeutic cells, which provides not only the proof-of-concept but also the ready-to-use new approach of T cell expansion for clinical immune therapy